Last reviewed · How we verify
NCT04564651
Platelet Transfusion in Acute-on Chronic Liver Failure
NA trial testing platelet transfusion in Acute-On-Chronic Liver Failure in 80 participants. Status unknown.
1 May 2024
Quick facts
| Lead sponsor | Nanfang Hospital, Southern Medical University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 1 May 2019 |
| Primary completion | 1 May 2024 |
| Estimated completion | 1 May 2024 |
| Sites | 8 locations across China |
Drugs / interventions tested
- platelet transfusion — full drug profile →
Conditions studied
- Acute-On-Chronic Liver Failure — all drugs for Acute-On-Chronic Liver Failure →
Sponsor
Nanfang Hospital, Southern Medical University
Who can join
Adults 16 to 60, any sex, with Acute-On-Chronic Liver Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute on-chronic liver failure (ACLF) is a severe liver disease with a 28-day mortality rate of up to 40%. When the patients get 3 or more organ failures, the 28-day mortality rate is up to 82.6%. Though the ACLF patients have high short-term mortality, and the only effective treatment method is liver transplantation. However, few patients can be treated due to the scarcity of liver source, rapid disease progression and short transplantation window. Our team evaluated the platelet function of 100 patients with ACLF by using the thromboelastograghy (TEG 5000). It was found for the first time that the reactivity of platelets of ACLF patients decreased, and the platelet inhibition rate (especially the ADP pathway) was related to patients'short-term prognosis. When the ADP inhibition rate was 70%, the patients'28-day mortality was up to 100%. However, the mechanism of low platelet response to ADP in ACLF patients is still unclear. We found that the platelet function in patients with ACLF 2-3 grade and inhibition rate beyond 70% was improved and the 28-day mortality decreased after platelet transfusion. Whether platelet transfusion can prolong survival time needs to be determined in a prospective controlled study. Therefore, this study is expected to find a new therapeutic method to reduce the mortality of patients with ACLF.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Design for a Multicentre Prospective Cohort for the Assessment of Platelet Function in Patients with Hepatitis-B-Virus-Related Acute-on-Chronic Liver Failure.
Jiang X, Chai S, Huang Y, Huang Z, et al · · 2022 · cited 1× · PMID 36042872 · DOI 10.2147/clep.s376068
Verify or expand the search:
- PubMed search for NCT04564651
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of platelet transfusion
Trials testing the same drug.
- NCT05399693 — Platelet Transfusion Refractoriness · completed
- NCT03968484 — Platelet Transfusion in Sepsis Trial · NA · withdrawn
Other recruiting trials for Acute-On-Chronic Liver Failure
Currently open trials in the same condition.
- NCT07198854 — Risk Factors Affecting MSC Efficacy in ACLF Patients · recruiting
- NCT06996392 — Phase I Trial of QH-1A Hybrid Bio-Artificial Liver With Ex Vivo Blood-Purifying MSCs in Acute-on-Chronic Liver Failure · Phase 1 · active not recruiting
- NCT06831565 — Comparison of Blood Products Required Using Two Different ROTEM Cut-offs Before Invasive Procedures in Cirrhosis and Acu · NA · recruiting
- NCT06562803 — Efficacy and Safety of Cytokine Adsorption and Plasma Exchange in Patients With ACLF and Sepsis · NA · recruiting
- NCT06079021 — COOLEY- Study: aCute On chrOnic Liver failurE Using the cYtosorb Device · NA · recruiting
Other Nanfang Hospital, Southern Medical University trials
Trials by the same sponsor.
- NCT07091994 — A Trial of Edaravone Dexborneol in Acute Ischemic Stroke With Active Malignancy · Phase 4 · not yet recruiting
- NCT06444022 — hAESCs Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation · Phase 1 · withdrawn
- NCT07537777 — Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted T · Phase 2 · not yet recruiting
- NCT07481032 — Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients · NA · not yet recruiting
- NCT07511894 — Beta-Blockers on the Efficacy of Neoadjuvant Immunotherapy for Gastric Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04564651 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nanfang Hospital, Southern Medical University
- Last refreshed: 25 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04564651.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing